Regenerative medicine in Korea, read carefully

“Regenerative” is a marketing category, not a single treatment. It covers products that differ enormously in what they contain — living cells, cell fragments, cell-free vesicles, or synthetic DNA fragments — and in how much evidence supports them. As of this review, no exosome product has United States FDA approval for any indication^[1], the strongest evidence in the whole category (PRP for pattern hair loss) was graded low certainty by the systematic reviewers themselves^[3], and Korea regulates cell-based interventions through a statute that requires institutional designation and committee review before an intervention may be conducted at all. This site explains those distinctions. It does not offer, price, or recommend any treatment.

Most people arriving here have already read a clinic page promising cellular renewal, or seen an advertisement for a “stem cell facial,” and want to know what part of it is real. That is a reasonable question and a surprisingly hard one to answer from search results, because the field mixes three separate things that are usually presented as one: a genuine and active area of biomedical research, a set of commercially available products whose evidence base is thin, and a marketing vocabulary that borrows the credibility of the first to sell the second.

This reference tries to keep them apart. Each page states what a modality actually is, what the best available published study design is, what that study design does and does not establish, and what a reader should ask before agreeing to anything. Where the honest answer is “we do not know yet,” the page says so — including where that answer is commercially inconvenient for the clinic that publishes this site.

The one distinction that organises everything else

Ask what is physically in the syringe. That single question sorts the field better than any brand name, because it predicts both what a regulator will call the product and what kind of study anyone has managed to run on it.

At one end sit preparations containing living nucleated cells — autologous mesenchymal stromal cells, stromal vascular fraction, adipose-derived cells. These are the products that the phrase “stem cell treatment” literally describes, and they are the most heavily regulated, because a living cell administered to a person can do things a molecule cannot. At the other end sit polynucleotides and PDRN: purified DNA fragments, in the case of PDRN derived from salmon sperm, containing no cellular material whatsoever^[4].

In between are two categories that cause most of the confusion. Platelet-rich plasma is your own blood, spun down so that platelets are concentrated in a small volume of plasma — anucleate cell fragments, not stem cells. And exosomes are small vesicles released by cells, which is to say a cell product without the cell. That last category is the one where the vocabulary has run furthest ahead of the science; the International Society for Extracellular Vesicles has had to publish successive editions of minimum reporting standards partly because laboratories could not agree on what they were even measuring^[5]. The difference between stem cells and exosomes is worth understanding before reading any clinic page on either.

Why the evidence question deserves a page of its own

“Studies show” is doing a lot of work in this field. A narrative review, a case series of eleven patients, a randomised controlled trial, and a meta-analysis of such trials are all “studies,” and they support conclusions of wildly different strength. The aesthetic exosome literature is currently dominated by the first two categories: a 2025 comprehensive review found early evidence supporting several indications while noting that the absence of standardisation in how exosomes are produced and applied limits what can be concluded from any of it^[2].

The instructive case is PRP, because it is the modality where the research community actually did the work. There are randomised trials, and there are meta-analyses of those trials. And the largest of them, covering 27 controlled trials and 1,117 subjects, concluded that evidence of benefit was limited and mostly of low quality, using formal GRADE assessment rather than an author’s impression^[3]. That is what a mature evidence base looks like in this field. Modalities with less research behind them are not better; they are just less examined. How to read evidence levels in regenerative medicine takes this apart in detail.

The regulatory picture, in two jurisdictions

Two regulators matter to most readers of this site, and they answer different questions. The United States FDA has published a standing consumer alert about regenerative medicine products including stem cells and exosomes, which is the document to read before accepting any claim of American regulatory blessing. Korea regulates advanced regenerative medicine through its own statute, which routes cell-based interventions through designated institutions and a review committee before they may be conducted.

Neither fact tells you whether a particular clinic is operating properly. That is the part readers most often get wrong: a statute existing is not a clinic being licensed under it, and a paper being published is not a product being approved. Both the Korean framework and the FDA-approval question have pages here that stay inside what the primary documents actually say.

Medical tourism raises the stakes

A reader considering travelling for a regenerative procedure is taking on a risk profile that a local patient does not. A critical review of international stem cell tourism found that clinics offering these therapies are concentrated in jurisdictions with lighter oversight, that reported complications include infection, immune rejection and tumour formation, and that follow-up care after returning home is frequently nobody’s responsibility^[6]. If you are reading this from outside Korea, the safety page and the list of questions to ask a clinic are the two most useful pages on this site.

How to read this site

This site is funded and medically reviewed by a dermatology clinic in Seoul, which is a conflict of interest and is disclosed in the footer of every page rather than buried. The consequence worth knowing as you read: no page here states that any clinic provides, is authorised to provide, or prices any of the interventions described, and where a modality’s evidence is weak the page says so. The editorial policy page names the publisher, sets out how sources are selected, and lists what is deliberately not published here.

Written by the Stem Cell Seoul editorial team and medically reviewed by a Korean Board-Certified Dermatologist (AAD International Fellow · ASLMS member). Last reviewed 2026-08-30.